Labena Ventures

Since 2017, ZORA has been a leader in Israel’s impact space as an early-stage deep tech investor based in Tel Aviv. We are: Pragmatists who see partnership between innovators and corporates as the fastest path to a cleaner and healthier future; Seekers of rare opportunities for game-changing global impact; Hands-on investors and operators who work intimately with our teams as they bring innovations from lab to field; Voracious learners who derive endless energy from the world-class scientists and teams we have the honor to back. Our community of changemakers extends to our investors who put their capital to work in pursuit of a brighter tomorrow. Vision & mission Israel’s deeptech ecosystem offers unparalleled R&D capable ofaddressing our planet’s largest challenge - managing climate change while ensuring a sustainable food supply for a growing population. Leveraging this research into deployable products for the world’s largest economic actors - global corporations - presents opportunity to effect meaningful change at unprecedented scale. We partner with Israel’s leading scientists and technologists to convert lab-scale innovations into mainstream food, agriculture and climate solutions that transform the way global business is done -- healthfully, sustainably and resource-efficiently. Leadership ZORA was founded by Vanessa Bartram in 2017. Vanessa is an impact entrepreneur turned impact investor. She began her career in investment banking in Mexico City, advising middle-market companies on M&A and restructuring. She later founded the Miami-based impact HR company WorkSquare, which she grew to over $25M in revenue. Vanessa holds an MBA from Harvard, a BA from Princeton, and is a Heritage Fellow with the Wexner Foundation.

The mission of the group is to identify early-stage companies with disruptive technologies that solve unmet needs in biologic drug R&D and production, as well as challenges in the diagnostics market. Investment selection is completed thorough a rigorous review process, which starts with in-depth market work, followed by due diligence according to Danaher’s best-in-class standard work.

At Menlo Ventures, we go ALL IN. This isn’t just a motto, but how we show up everyday for the companies we back, the investors who back us, and each other. When we win, we win as a team. 47 Years 80+ Public Companies 165 + Mergers + Aquisitions $5B+ Under Management We focus on the "three stages of early" We are investors and company builders - we know what it takes to turn a budding idea into a scalable business. We work with early-stage founders to find product-market fit, develop go-to-market strategies, scale their organizations, and support them as they grow. Inception: Our Menlo Labs team helps founders validate early-stage ideas, de-risk opportunities, and build successful foundations. Venture: Our venture team provides series A and B startups with guidance and hands-on help as they build their teams and products. Inflection: Our inflection team supports early growth-stage startups during critical points as they prepare to scale. Our focus areas At every stage from inception through IPO, we invest in game-changing ideas that reinvent life and work. Although we remain open to new ventures within consumer, enterprise, and healthcare, we go deep in the following seven focus areas: AI: Generative AI is breaking into every software vertical, and winners in these markets will create massive economic and societal value. Menlo Ventures is placing bets on the most promising GenAI companies at the infrastructure and application layers, where we see immense potential for groundbreaking businesses that will reshape industries and push the boundaries of what we can achieve. Bio + Healthcare: Innovations at the intersection of advancements in technology and biology will drive major improvements in the quality of our health and the cost of healthcare. At Menlo, we invest at that intersection - backing breakthrough digital health companies (vertical SaaS and digital care) and novel life sciences companies (therapeutic platforms and transformative technologies). Consumer: The world we live in today is enhanced by technologies we might not have thought possible even 10 years ago. There is so much still to come. At Menlo, we invest in the game-changing companies of the future, those that will help us do things better, faster, or cheaper than we can today. Cloud Infrastructure: As enterprises continue migrating to the public cloud, a new generation of companies will write the playbook for the underlying infrastructure that powers their applications. These tools and platforms are built for and cater to the developer, optimized for time-to-integration with beautiful, easy-to-use UIs and APIs. Cybersecurity: In a complex, post-pandemic world, rapid cloud adoption and the proliferation of open-source software have dramatically expanded the attack surface for bad actors against enterprises, governments, and their applications. Additionally, the shift-left approach to software development requires developers to embrace a security-first mindset. As the cyber war continues, Menlo will back the best teams fighting on the frontlines. Fintech: Financial transactions and services power the global economy. Menlo invests in four fintech categories: dev-focused infrastructure and embedded finance (API layers), vertical banking, end-to-end financial services for consumers and SMBs, and tools that serve finance teams and the office of the CFO. SaaS: The shift to the cloud introduced an entirely new business model–Software-as-a-Service–and created unprecedented opportunities for enterprise software companies. Menlo divides the SaaS landscape into three categories, each with a distinct point of view that guides our investment, research, and resources: Departmental SaaS, Vertical SaaS, and Horizontal SaaS. Supply Chain + Automation: This once-in-a-generation reinvention/reinvigoration of the supply chain will create a world that is more efficient, resilient, and sustainable because of the operational efficiencies we gain. With an eye on a more functional future, Menlo invests in a broad range of technologies–robotics and industrial automation among them.

Empowering life science innovators to reach their full potential by providing strategic financial guidance and unlocking global investment opportunities. Your Strategic Partner for Fundraising in Life Sciences Our proven track record makes us your trusted partner for your fundraising journey 2 exits in 2024 through Gold Nest Capital - Group's asset management company USD 50 M raised in 2024 for life science companies 151 company due diligences since 2020 as investment opportunities/services 100% client satisfaction for three years running 75% requests to renew for three years running 1 biomanufacturing company founded in 2023

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

Positron Ventures helps and funds Europe-based scientist-entrepreneurs who are pursuing moonshots for (planetary) health. We invest in scientist-entrepreneurs working on a breakthrough in their field, across the natural sciences. We back teams from day one in their pursuit of solving a major global challenge. We do this with pre-seed investments and, wherever needed, support across all aspects of building a company. If you are looking for funding, check out our investment criteria and shopping list, and our view on when to engage. If you think there might be a match, contact us at startups@positron.vc. Scientists who have not yet spun out a company but are interested in doing so, please check our scientist resources.